Amlintide
Source Amlintide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Amlintide is a synthetic version of the pancreatic beta‑cell hormone amylin. It has been investigated in a small human study to characterize its distribution volume, clearance, and residence time after intravenous administration. The compound’s therapeutic role and regulatory status remain undefined.
Mechanism of Action
No mechanism recorded yet.
What the Research Shows
A pharmacokinetic study in nine healthy male volunteers examined the disposition of intravenously administered synthetic amylin (amlintide) at a dose of 50 µg. Endogenous amylin release was suppressed with somatostatin, and plasma concentrations were fitted to a three‑exponential model. The apparent volume of distribution was 173 ± 16 mL·kg⁻¹, comparable to insulin. Mean residence time was 27.7 ± 2.1 min, about twice that of insulin. Total body clearance was 6.2 ± 0.2 mL·kg⁻¹·min⁻¹, with a fractional clearance of 0.038 ± 0.003 min⁻¹, slower than insulin and similar to C‑peptide. These data suggest amlinitde persists longer in circulation than insulin.
Limitations of the Evidence
Evidence is limited to a single, small‑scale pharmacokinetic study in healthy males; no data on pharmacodynamics, therapeutic efficacy, or safety are provided. The study used an artificial suppression of endogenous amylin, which may not reflect typical physiological conditions. Consequently, conclusions about clinical utility are lacking.
How It Is Administered
In the reported study, amlinitde was administered intravenously as a single 50 µg bolus. The preparation was a synthetic peptide solution; no details on formulation or other routes of administration were described.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLow1997-01-01T00:00:00.000000Z
- Journal ArticleLowClodi M, et al.1998-01-01T00:00:00.000000Z
Frequently Asked Questions
What is amlinitde?
Amlintide is a laboratory‑synthesized peptide that replicates the structure of the hormone amylin, which is co‑secreted with insulin by pancreatic beta cells.
How has amlinitde been studied in humans?
A single study gave healthy male volunteers an intravenous 50 µg dose while suppressing their own amylin production with somatostatin, then measured blood levels over time to determine distribution and clearance.
What are the known pharmacokinetic properties of amlinitde?
The peptide shows a volume of distribution around 173 mL·kg⁻¹, a mean residence time of roughly 28 minutes, and a total body clearance of about 6 mL·kg⁻¹·min⁻¹, indicating slower elimination than insulin.
Is amlinitde approved for medical use?
The abstracts provide no information on regulatory approval; its status is listed as unknown, and the available data pertain only to experimental pharmacokinetic assessment.
What are the limitations of the current knowledge about amlinitde?
Research is confined to a small pharmacokinetic trial in healthy subjects, lacking data on efficacy, safety, dosing regimens, or real‑world therapeutic outcomes.